Under construction – not a live service
Sign in
Taking peoplePhase 1

Tests IEV407 alone or with endocrine therapy in advanced breast cancer

Tests IEV407, alone or with endocrine therapy, in adults with advanced breast cancer.

Key facts

Who runs it
Novartis Pharma AG
Where
Frankfurt Am Main and Ulm, GermanySee the 2 sitesAlso in 4 other countries, 6 sites
Trial code
Registry title
A clinical trial to learn about the effects of IEV407 when given alone or with endocrine therapy in people with advanced breast cancer
Status
Recruiting
Phase
Phase 1
People taking part
40 people, planned
Started
30 Sept 2026
Expected to end
8 Jun 2032
Type of study
Interventional
Record updated
21 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced breast cancer of the HR+/HER- type. IEV407 is given alone or together with endocrine therapy.

Age
18 years or older
Sex
Men and women can join.
Disease stage
Advanced HR+/HER- breast cancer

Where in Germany

Also in 4 other countries, 6 sites

  • Goethe University FrankfurtFrankfurt Am Main, GermanyNot yet recruiting
  • Universitaetsklinikum Ulm AoRUlm, GermanyNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests IEV407 alone or with endocrine therapy in advanced breast cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
21 October 2026